The modality is outside your comfort zone
Your partners can follow the deck. They cannot quickly stress-test biology, manufacturing, and the path to clinic—or spot where prior packages in the class failed.
BioticaBio
Independent science diligence · seed & Series A
Know what has to be true—before you write the check.
You are about to put $1–10M into a complex biotech or medtech package. BioticaBio turns the pitch into the claims that must hold for the deal to work, checks each one against published science and known failures, and returns a memo with sources: what holds, what conflicts, and what is still unknown.
Tempus is a major precision-medicine company that uses biomedical data and knowledge graphs to test drug-development hypotheses for industry. BioticaBio does that job for investors: test the investment thesis against published evidence, then write what it means for the check.
Decision Sprint · fixed scope · NDA before data room · timed to your deal deadline
- Lean seed & Series A teams
- $1–10M biotech / medtech checks
- Live deal under a deadline
- Claims checked against published science
- Partner memo with sources
- NDA before the data room
When buyers call us
You do not need more slides. You need a call you can defend.
A clean mechanism still dies on translation, CMC, differentiation, or financing. We put those dependencies on the page so you walk into the partner meeting knowing where the thesis is strong, contested, or empty.
The evidence cuts both ways
There is real support and real contradiction. You need a written map: which claims hold against the literature and trials, which rest on inference, and what to ask management before you commit.
The clock is real and the bench is thin
You have a partner meeting or term-sheet deadline and no full cross-functional diligence team. You need outside science review for that call—not a multi-month consulting engagement.
What you buy
One Decision Sprint on the live deal. A short triage if you are not ready to go deep.
Independent scientific diligence for lean seed and Series A teams: take one opportunity, pressure-test the science case, and deliver a memo your partners use in the decision meeting.
Primary · Decision Sprint
Science diligence on one live opportunity—claims checked against published evidence, written for the investment decision.
- Pricing
- On inquiry
- Timing
- Your deal clock
- You walk away with
- Partner-ready memo
- Two-page decision brief + claim-by-claim evidence map with sources
- Risk register, prior-failure context, and questions for management
- ~20–30 page memo and a 60-minute partner briefing
Optional · Signal Screen
Five-claim triage before you open the full sprint
Deck plus public sources only. Pricing on inquiry; credited toward a Decision Sprint started within 30 days of the screen. Use it for a quick dig-deeper / pass before locking full scope.
Not the lead offer. Ask for it after fit discussion.
Mention Signal Screen in your fit request →Prior modality work
Modalities we have reviewed under a live clock.
Anonymized accounts: what claims got tested, what triggers showed up, and where the sprint stopped. No client names or outcomes.
Anonymized prior work
Cell therapy
Early investment and partnership reviews of autologous and allogeneic cell programs, including platform-plus-pipeline structures where the thesis mixed product claims with manufacturing and control-strategy readiness.
Decision pressure
Term-sheet timing forced a sharp cut between what was demonstrated in limited clinical/process packages versus what still depended on unproven scale, release, or comparability assumptions.
Boundary
Did not substitute for formal CMC, regulatory, or clinical-statistical opinions; flagged when those were required.
Claims usually tested
- Whether potency and product identity claims were solid enough for the proposed next study
- Whether CMC / process control risk would consume the raise before a claim-resolving readout
- Whether comparator and failed-analogue programs actually supported the differentiation story
Example decision triggers
- Potency assay or release strategy not yet tied to the clinical claim
- Comparability after process change left as narrative rather than a plan
- Use of proceeds not mapped to the manufacturing gates that have to clear
Related decision notes
Accounts are anonymized. Client names, confidential findings, and investment outcomes are omitted. These describe kinds of reviews we have run—not case studies with results.
Who this is for
Fit and not fit.
Pricing is set after fit discussion from modality complexity, evidence access, deadline, and scope. Signal Screen is optional and only after that conversation—not the homepage lead.
Fit
- U.S. seed / Series A investor writing $1–10M biotech or medtech checks
- Technically complex package—advanced therapeutics, diagnostics, or regulated devices
- A live decision with a real clock (partner meeting, term sheet, syndication, follow-on)
- Thin or incomplete internal science / CMC / regulatory bench for this modality
- You want the thesis challenged, not validated for marketing
Not fit
- Mega-funds that already staff complete specialist diligence benches
- Buyers who need legal FTO, regulatory sign-off, audit, or clinical-statistical reanalysis
- Founders seeking promotional validation of a pitch
- Zero-budget angels or general market-education projects
- Deals where source access makes the stated deadline fake
Questions investors ask first
Straight answers.
We are a lean team without a full biotech diligence bench. Is this for us?
Yes, if you have a live $1–10M decision on a technically complex opportunity. BioticaBio is for seed and Series A teams that need an independent science read before they commit—not a standing outsourced specialist shop.
How is pricing set?
On inquiry. Quote follows fit discussion and depends on modality complexity, evidence access, deadline, and scope. There is no public rate card on this site.
How is this different from a large life-science diligence firm?
Large firms staff matched specialists across clinical, CMC, regulatory, IP, and commercial for full transactions. We do a shorter job: pull the claims that must be true for your deal, check them against published literature, trials, targets, and known failures, and write what that means for the investment call. Domains outside scope are listed as unreviewed.
What does the knowledge graph do?
It links papers, trials, targets, labels, patents, and failure modes so each material claim is checked for support and contradiction—not retold from the deck. A human writes the investment synthesis. You get sources attached. You do not get a black-box score.
Go deeper
Method, prior work, and background.
Have a live deal on the calendar?
Tell us stage, modality, deadline, and the claims creating the most uncertainty. We reply on fit within one business day—before any confidential materials change hands.
Scope a live deal
For $1–10M biotech and medtech checks. No file uploads on this form.